Exploratory clinical trial of dendritic cell vaccine pulsed with neoantigen peptides for malignant tumor.

Takimoto Rishu0 个研究点目标入组 60 人开始时间: 2020年1月10日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•(1)Be diagnosed with malignant tumor by imaging findings or pathological or cytological study.
•(2)Have a successful genetic analysis of tumor sample tested by one of the clinical laboratories assigned by at Seta Clinic Tokyo.
•(3)Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1.
•(4)Visit outpatient department on schedule.
•(5)Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed.
•(6)Provide written consent to participate this study.

•(1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia.
•(2)Have a history of a serious drug allergy.
•(3)Have a positive result of HIV antibody.
•(4)Have a serious cardiac disorder.
•(5)Have an active autoimmune disorder.
•(6)Have a concurrent cancer.
•(7)Have an infectious disorder that is difficult to control.
•(8)Be a female who is pregnant, lactating, or with a possibility of pregnancy.

发起方

Takimoto Rishu